טוען...
Germlining of the HIV-1 broadly neutralizing antibody domain m36
Engineered antibody domains (eAds) have emerged as a novel class of HIV-1 inhibitors and are currently under preclinical testing as promising drug candidates for prevention and therapy of HIV-1 infection. Reverse mutation of antibodies to germline sequences (germlining) could not only identify less...
שמור ב:
| הוצא לאור ב: | Antiviral Res |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4357557/ https://ncbi.nlm.nih.gov/pubmed/25676867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2015.02.001 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|